Markets

Regulus Therapeutics Inc. Enters Oversold Territory - Tale of the Tape

Regulus Therapeutics Inc.'s ( RGLS ) share price has entered into oversold territory with an RSI value of 29.23. The Zacks Consensus Estimate on Regulus Therapeutics Inc.'s earnings for the full year period has loss of 0.00 cents over the past two months to $-0.74 per share. Currently, Regulus Therapeutics Inc. is a Zacks #2 Rank ("Buy"), suggesting that now might be a good time to get in on ( RGLS ) after its recent drop.

REGULUS THERAP (RGLS): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

RGLS

Other Topics

Investing Stocks

Latest Markets Videos